Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-10-25-Speech-2-292"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20051025.22.2-292"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, the provisions of the Directive of the European Parliament and of the Council on the legal protection of biotechnological inventions do not regulate in detail all the problems associated with the development of genetic engineering and biotechnology. In July 2005, the Commission presented a second report to the Council and Parliament on the development and implications of patent law in the field of biotechnology and genetic engineering.
I believe that it would be premature to adopt a position on the matter of whether patents on gene sequences and DNA sequences should be allowed according to the traditional model of patent claims, whereby a first inventor can claim an invention. Instead, we should continue to monitor the possibility that legislative disparities between Member States could have an economic impact.
I am in favour of the Commission’s initiative to undertake studies analysing the extent to which human DNA has been patented in Europe, and the possible consequences that this may have for research and innovation. These studies should also incorporate legal, ethical and social aspects. Turning to the issue of totipotent stem cells, I do not believe that they should be patented, due to the implications that this would have for human dignity.
I expect the Commission to take appropriate steps to establish a clearer and more predictable legal framework for biotechnological inventions. This framework should be informed by ethical considerations, and at the same time create a favourable climate for innovation and scientific and business development."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples